A. Mast

A. Mast, S. Maroney, 2008, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass

B. Donahue, A. Mast, D. Gailani, 2006, Journal of thrombosis and haemostasis : JTH.

Active tissue factor pathway inhibitor is expressed on the surface of coated platelets.

A. Mast, G. Dale, M. L. Collins, 2007, Blood.

Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery

J. Peterson, A. Mast, R. Bercovitz, 2018, Thrombosis and Haemostasis.

Heparin–protamine balance after neonatal cardiopulmonary bypass surgery

A. Mast, R. Bercovitz, R. Woods, 2018, Journal of thrombosis and haemostasis : JTH.

Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor

A. Mast, S. Maroney, K. Hansen, 2013, Current opinion in hematology.

Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue‐specific fibrin deposition

H. Weiler, A. Mast, B. Cooley, 2007, Journal of thrombosis and haemostasis : JTH.

GWAS of complete blood count (CBC) measures in 13,403 blood donors in the multi-racial RBC-omics study reveal novel genetic loci in minority populations which provide insights into the pathways that may connect them to disease

G. Page, S. Kleinman, M. Busch, 2017 .

Oral iron supplementation after blood donation: a randomized clinical trial.

S. Glynn, S. Kleinman, D. Brambilla, 2015, JAMA.

Tissue factor and factor VIIa--hemostasis and beyond.

A. Wolberg, A. Mast, 2012, Thrombosis research.

Protein S Is a Cofactor for Platelet and Endothelial Tissue Factor Pathway Inhibitor-&agr; but Not for Cell Surface–Associated Tissue Factor Pathway Inhibitor

A. Mast, P. Ellery, S. Maroney, 2014, Arteriosclerosis, thrombosis, and vascular biology.

Intradonor reproducibility and changes in hemolytic variables during red blood cell storage: results of recall phase of the REDS‐III RBC‐Omics study

Marion C Lanteri, M. Gladwin, G. Page, 2018, Transfusion.

FcRn augments induction of tissue factor activity by IgG-containing immune complexes.

L. Rauova, M. Poncz, D. Cines, 2020, Blood.

Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy

S. Glynn, T. Ganz, M. Busch, 2013, Haematologica.

Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin.

J. Enghild, S. Pizzo, G. Salvesen, 1991, Biochemistry.

Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein.

A. Mast, 2016, Arteriosclerosis, thrombosis, and vascular biology.

Targeting TFPI for hemophilia treatment.

J. Peterson, A. Mast, S. Maroney, 2016, Thrombosis research.

Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.

J. Enghild, A. Mast, K. Hasty, 2002, The Biochemical journal.

Behavioral, biochemical, and genetic analysis of iron metabolism in high‐intensity blood donors

D. Bellissimo, D. Witcher, V. Wroblewski, 2008, Transfusion.

The contribution of TFPIα to the hemostatic response to injury in mice

R. Simari, L. Brass, M. Tomaiuolo, 2021, Journal of thrombosis and haemostasis : JTH.

Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis.

R. Simari, J. V. van Deursen, T. White, 2010, Blood.

Iron status of blood donors

A. Mast, B. Spencer, 2022, Current opinion in hematology.

Demographic, clinical, and biochemical predictors of pica in high‐intensity blood donors

G. Page, R. Burns, A. Mast, 2022, Transfusion medicine.

PREVALENCE OF IRON DEFICIENCY IN BLOOD DONORS

A. Mast, B. Spencer, 2022 .

Association of proton pump inhibitor and histamine H2-receptor antagonists with restless legs syndrome

H. Ullum, K. Burgdorf, G. Page, 2020, Sleep.

The price of blood is measured in iron

E. Murphy, A. Mast, 2017, The Lancet.

Reduced Prothrombinase Inhibition by Tissue Factor Pathway Inhibitor Contributes to the Factor V Leiden Hypercoagulable State.

A. Mast, L. Baumann Kreuziger, P. Ellery, 2017, Blood advances.

Tissue factor pathway inhibitor is an inhibitor of factor VII‐activating protease

L. Aarden, A. Mast, D. Wouters, 2012, Journal of thrombosis and haemostasis : JTH.

Low normal factor V enhances thrombin generation in hemophilia A by a substrate competition mechanism with factor Xa

Suzanne S. Sindi, A. Fogelson, S. Sindi, 2022, bioRxiv.

Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength

J. Heemskerk, A. Mast, J. Cosemans, 2018, Thrombosis and Haemostasis.

Major Reservoir for Heparin-Releasable TFPIα (Tissue Factor Pathway Inhibitor α) Is Extracellular Matrix

J. Peterson, A. Mast, N. D. Martinez, 2021, Arteriosclerosis, thrombosis, and vascular biology.

Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)α and TFPIβ

A. Mast, P. Ellery, N. D. Martinez, 2013, Journal of thrombosis and haemostasis : JTH.

Murine Hematopoietic Cell Tissue Factor Pathway Inhibitor Limits Thrombus Growth

A. Mast, Catherine E. Bonesho, B. Cooley, 2011, Arteriosclerosis, thrombosis, and vascular biology.

Alternatively spliced isoforms of tissue factor pathway inhibitor.

A. Mast, P. Ellery, S. Maroney, 2010, Thrombosis research.

Tissue factor pathway inhibitor‐γ is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans

A. Mast, S. Maroney, J. Ferrel, 2008, Journal of thrombosis and haemostasis : JTH.

Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin).

K. Suzuki, J. Enghild, S. Pizzo, 1991, The Journal of biological chemistry.

Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor.

A. Mast, Catherine E. Bonesho, P. Ellery, 2012, The Biochemical journal.

Sex hormone intake in female blood donors: impact on haemolysis during cold storage and regulation of erythrocyte calcium influx by progesterone.

G. Page, S. Kleinman, M. Busch, 2019, Blood transfusion = Trasfusione del sangue.

Qualitative assessment of pica experienced by frequent blood donors

Melanie C. Chansky, A. Mast, R. Cable, 2017, Transfusion.

Restless legs syndrome, pica, and iron status in blood donors

S. Glynn, S. Kleinman, D. Rye, 2013, Transfusion.

Limited proteolysis of alpha 1-proteinase inhibitor (alpha 1-PI) in acute leukemia: studies on the resulting fragments and implication for the structure of the inactivated inhibitor.

F. Lottspeich, B. Emmerich, A. Mast, 1995, Biological chemistry Hoppe-Seyler.

In vivo catabolism of α1-antichymotrypsin is mediated by the Serpin receptor which binds α1-proteinase inhibitor, antithrombin III and heparin cofactor II

S. Feldman, S. Pizzo, G. Salvesen, 1988 .

A GPI‐anchored co‐receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression

D. Dietzen, R. Brodsky, A. Mast, 2006, Journal of thrombosis and haemostasis : JTH.

New insights into the biology of tissue factor pathway inhibitor

A. Mast, S. Maroney, 2015, Journal of thrombosis and haemostasis : JTH.

The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.

J. Saffitz, A. Schwartz, G. Bu, 1995, The Journal of clinical investigation.

Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor.

A. Schwartz, A. Mast, G. Broze, 1997, The Biochemical journal.

Alternatively spliced tissue factor pathway inhibitor: functional implications.

A. Mast, 2011, Frontiers in bioscience.

Characterization of the Association of Tissue Factor Pathway Inhibitor With Human Placenta

D. Dietzen, A. Mast, C. L. Hall, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.

A. Mast, J. Lockett, 2002, Biochemistry.

Evaluation of the rapid plasma elimination of recombinant alpha 1-proteinase inhibitor: synthesis of polyethylene glycol conjugates with improved therapeutic potential.

S. Pizzo, G. Salvesen, A. Mast, 1990, Journal of Laboratory and Clinical Medicine.

Proteolytic inactivation of alpha-1-anti-chymotrypsin. Sites of cleavage and generation of chemotactic activity.

J. Potempa, A. Mast, J. Travis, 1991, The Journal of biological chemistry.

Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation

Susan A Maroney, R. Camire, A. Mast, 2013, Proceedings of the National Academy of Sciences.

Acquired factor V deficiency in a patient without evidence of a classical inhibitor

A. Neff, A. Mast, D. Gailani, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia

A. Mast, Catherine E. Bonesho, P. Johansen, 2012, Proceedings of the National Academy of Sciences.

Donor genetic and nongenetic factors affecting red blood cell transfusion effectiveness

Sarah E. Reese, M. Gladwin, G. Page, 2021, JCI insight.

A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm

Angelica M. Walker, B. Aronow, A. Justice, 2020, eLife.

Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency.

D. Dietzen, A. Mast, M. Blinder, 2002, Blood.

Intersection of regulatory pathways controlling hemostasis and hemochorial placentation

E. Grundberg, M. Ema, T. Arima, 2021, Proceedings of the National Academy of Sciences.

Large genome-wide association study identifies three novel risk variants for restless legs syndrome

J. Danesh, H. Stefánsson, T. Sigmundsson, 2020, Communications Biology.

Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study.

Grier P Page, Mars Stone, Yuelong Guo, 2017, Blood advances.

Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells.

C. Hillard, H. Weiler, A. Mast, 2006, Blood.

Multi-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage.

Marion C Lanteri, M. Gladwin, G. Page, 2021, The Journal of clinical investigation.

Sex-specific genetic modifiers identified susceptibility of cold stored red blood cells to osmotic hemolysis

M. Gladwin, G. Page, D. Triulzi, 2022, BMC Genomics.

2016 proceedings of the National Heart, Lung, and Blood Institute's scientific priorities in pediatric transfusion medicine

S. Glynn, S. Stanworth, P. Spinella, 2017, Transfusion.

Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception

A. Mast, J. Sheehan, P. Westmark, 2018, Arteriosclerosis, thrombosis, and vascular biology.

Blood, sweat, and tears: Red Blood Cell‐Omics study objectives, design, and recruitment activities

Grier P Page, Donald J Brambilla, Mars Stone, 2018, Transfusion.

Biospecimen repositories: are blood donors willing to participate?

Erik A. Scott, M. Busch, A. Mast, 2010, Transfusion.

A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development.

J. Luyendyk, H. Weiler, A. Mast, 2015, Blood.

SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung

B. Aronow, A. Wolberg, A. Mast, 2021, eLife.

Teenage Blood Donors: Are We Asking Too Little and Taking Too Much?

H. Klein, C. Josephson, E. Bloch, 2017, Pediatrics.

Expression of Tissue Factor Pathway Inhibitor (TFPI) by Brain Endothelium

A. Mast, S. Maroney, J. Ferrel, 2008 .

Assessing Blood Clotting and Coagulation Factors in Mice

R. Westrick, A. Mast, L. Ivanciu, 2019, Current protocols in mouse biology.

Demographic, clinical, and biochemical predictors of pica in a large cohort of blood donors

G. Page, A. Mast, B. Spencer, 2020, Transfusion.

Translation of Human Tissue Factor Pathway Inhibitor-&bgr; mRNA Is Controlled by Alternative Splicing Within the 5′ Untranslated Region

M. Wickens, A. Mast, P. Ellery, 2014, Arteriosclerosis, thrombosis, and vascular biology.

Localization of tissue factor pathway inhibitor to lipid rafts is not required for inhibition of factor VIIa/tissue factor activity

D. Dietzen, A. Mast, C. L. Hall, 2003, Thrombosis and Haemostasis.

Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency.

M. Lawlor, A. Mast, Amy Pan, 2019, Blood advances.

Iron deficiency in blood donors: the REDS‐II Donor Iron Status Evaluation (RISE) study

S. Glynn, T. Simon, L. Tobler, 2012, Transfusion.

In Vitro Flow Evaluation of Recombinant Tissue Factor Pathway Inhibitor Immobilized on Collagen Impregnated Dacron

A. Mast, C. L. Hall, Sirisha Patchipulusu, 2004, ASAIO journal.

The benefits of iron supplementation following blood donation vary with baseline iron status

A. Szabo, A. Mast, R. Cable, 2020, American journal of hematology.

Intrauterine lethality in Tfpi gene disrupted mice is differentially suppressed during mid‐ and late‐gestation by platelet TFPIα overexpression

A. Mast, Amy E. Siebert, N. D. Martinez, 2021, Journal of thrombosis and haemostasis : JTH.

Iron status and self‐reported fatigue in blood donors

L. Wise, M. Fox, A. Mast, 2020, Transfusion.

Laboratory variables for assessing iron deficiency in REDS‐II Iron Status Evaluation (RISE) blood donors

T. Simon, E. Murphy, P. Carey, 2013, Transfusion.

Low hemoglobin deferral in blood donors.

A. Mast, 2014, Transfusion medicine reviews.

Iron deficiency in blood donors: analysis of enrollment data from the REDS‐II Donor Iron Status Evaluation (RISE) study

S. Glynn, T. Simon, A. Mast, 2011, Transfusion.

Elevated risk for iron depletion in high‐school age blood donors

S. Glynn, S. Kleinman, A. Mast, 2019, Transfusion.

The Relationship between Heavy Menstrual Bleeding, Iron Deficiency, and Iron Deficiency Anemia.

M. Munro, S. O’Brien, P. Kouides, 2023, American journal of obstetrics and gynecology.

Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy

W. Ruf, A. Mast, 2022, Journal of thrombosis and haemostasis : JTH.

Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice

R. Simari, A. Mast, J. McVey, 2009, Journal of thrombosis and haemostasis : JTH.

Factor Xa inhibition by immobilized recombinant tissue factor pathway inhibitor

A. Mast, C. L. Hall, F. Zaman, 2006, Journal of biomaterials science. Polymer edition.

Platelet tissue factor pathway inhibitor modulates intravascular coagulation.

A. Mast, S. Maroney, 2012, Thrombosis research.

Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis

S. E. Reese, S. Kleinman, E. Hod, 2023, Transfusion.

Estimates of total body iron indicate 19 mg and 38 mg oral iron are equivalent for the mitigation of iron deficiency in individuals experiencing repeated phlebotomy

D. Wright, A. Mast, R. Cable, 2017, American journal of hematology.

Red Blood Transfusion Does Not Increase Risk for Venous or Arterial Thrombosis

G. Edgren, D. Brambilla, A. Mast, 2018 .

Effect of iron supplementation on iron stores and total body iron after whole blood donation

S. Glynn, S. Kleinman, D. Brambilla, 2016, Transfusion.

The operational implications of donor behaviors following enrollment in STRIDE (Strategies to Reduce Iron Deficiency in blood donors)

A. Mast, R. Cable, J. Kiss, 2017, Transfusion.

A randomized, blinded, placebo‐controlled trial of education and iron supplementation for mitigation of iron deficiency in regular blood donors

A. Mast, R. Cable, J. Kiss, 2016, Transfusion.

The strategies to reduce iron deficiency in blood donors randomized trial: design, enrolment and early retention

A. Mast, R. Cable, J. Kiss, 2015, Vox sanguinis.

In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II.

S. Feldman, S. Pizzo, G. Salvesen, 1988, Biochimica et biophysica acta.

Putting donor health first in strategies to mitigate donor iron deficiency

A. Mast, 2017, Transfusion.

Frequent blood donations alter susceptibility of red blood cells to storage‐ and stress‐induced hemolysis

Grier P Page, Mars Stone, Yuelong Guo, 2018, Transfusion.

Factor V east Texas variant causes bleeding in a three‐generation family

J. Peterson, A. Mast, N. D. Martinez, 2021, Journal of thrombosis and haemostasis : JTH.

Platelet anticoagulant proteins: Modulators of thrombosis propensity within a procoagulant cell

A. Mast, Amy E. Siebert, 2020, Journal of thrombosis and haemostasis : JTH.

Mast Paul E . R . Ellery , Susan A . Maroney , Nicholas D . Martinez , Marvin P . Wickens and Alan E . Untranslated Region ′ Alternative Splicing Within the 5 mRNA Is Controlled

A. Mast, P. Wickens, 2013 .

Tissue factor pathway inhibitor and bacterial infection

A. Mast, S. Maroney, 2011, Journal of thrombosis and haemostasis : JTH.

Sex-specific genetic modifiers identified susceptibility of cold stored red blood cells to osmotic hemolysis

M. Gladwin, G. Page, D. Triulzi, 2022, BMC genomics.

Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage

Marion C Lanteri, M. Gladwin, V. Gordeuk, 2021 .

Evaluating surface bound rTFPI through an in vitro model of vessel wall injury.

A. Mast, C. L. Hall, F. Zaman, 2011, Thrombosis research.

Curbing an inhibitor for hemostasis.

A. Mast, G. Gilbert, 2011, Blood.

The health implications of low hemoglobin deferral in infrequent blood donors

D. Leitch, A. Mast, M. Delaney, 2015, Transfusion.

Red blood cell transfusion does not increase risk of venous or arterial thrombosis during hospitalization

G. Edgren, D. Brambilla, A. Mast, 2020, American journal of hematology.

Iron chelation therapy in patients with transfusion‐dependent myelodysplastic syndrome

A. Mast, Joshua J Field, 2012, Transfusion.

Low hemoglobin deferral in blood donors.

A. Mast, 2014, Transfusion medicine reviews.

Biospecimen repositories: are blood donors willing to participate?

Erik A. Scott, A. Mast, K. Schlumpf, 2010, Transfusion.

Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor.

A. Mast, P. Ellery, S. Maroney, 2012, The Biochemical journal.

Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.

J. Burthem, A. Wolberg, A. Mast, 2022, Journal of thrombosis and haemostasis : JTH.

The difference between fingerstick and venous hemoglobin and hematocrit varies by sex and iron stores

A. Mast, R. Cable, W. Steele, 2012, Transfusion.